Session title: Late breaker session
Time, date and location of session: 14. April 2018, 05:00 PM - 05:15 PM, Main Plenary
Presenter: Jens Ricke, Germany
Abstract: The impact of combining selective internal radiation therapy (SIRT) with sorafenib on overall survival in patients with advanced
Ad Statistics
Times Displayed: 125799
Times Visited: 7246 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
hepatocellular carcinoma: The SORAMIC trial palliative cohort (5449)
References
1. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.
2. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
3. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
4. National Institutes of Health, US National Library of Medicine: ClinicalTrials.gov. Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer (SORAMIC). Available from: https://clinicaltrials.gov/ct2/show/study/NCT01126645. Last accessed: March 2018.
5. Salem R, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52-64.
6. Sangro B, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868-78. ?
Back to HCB News
